More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Half of those surveyed plan to raise deductibles and maximum out-of-pocket costs for workers. Read more at straitstimes.com. Read more at straitstimes.com.

Biocon plans to launch generic copies of Wegovy in India and Canada within two years, targeting a growing drug market ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

According to a new feature by the Washington Post, approximately 16 million American adults are on GLP-1 drugs such as ...

I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.